NCT02385760View on ClinicalTrials.gov

CTX-4430 for the Treatment of Moderate to Severe Facial Acne Vulgaris

PHASE2CompletedINTERVENTIONAL
Enrollment

124

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

May 31, 2016

Study Completion Date

August 31, 2016

Conditions
Acne Vulgaris
Interventions
DRUG

CTX-4430

DRUG

Placebo

Trial Locations (10)

2000

Central Sydney Dermatology, Sydney

2217

St George Dermatology, Kogarah

2606

Clinical Trials Woden Dermatology, Phillip

3053

Skin and Cancer Foundation, Carlton

3210

Clinical Trials New Zealand, Hamilton

4000

Siller Medical, Brisbane

4102

Veracity Clinical Research, Woolloongabba

4217

The Skin Centre, Benowa

6160

Fremantle Dermatology, Fremantle

Unknown

Optimal Clinical Trials, Auckland

Sponsors

Lead Sponsor

Celtaxsys, Inc.
All Listed Sponsors
collaborator

Clinical Network Services (CNS) Pty Ltd

INDUSTRY

collaborator

Celtaxsys Aus Pty Limited

INDUSTRY

lead

Celtaxsys, Inc.

OTHER

NCT02385760 - CTX-4430 for the Treatment of Moderate to Severe Facial Acne Vulgaris | Biotech Hunter | Biotech Hunter